Silverback Therapeutics
500 Fairview Ave N
Suite 600
Seattle
WA
98109
United States
Tel: (206) 456-2900
Website: https://silverbacktx.com/
51 articles about Silverback Therapeutics
-
Silverback Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
8/12/2021
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, reported financial results for the second quarter ended June 30, 2021 and provided a business update.
-
Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
8/3/2021
Silverback Therapeutics, Inc. today announced that the Company will participate in the 2021 Wedbush PacGrow Healthcare Conference from August 10-11, 2021.
-
Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo® (cemiplimab), initially in HER2-expressing Non-Small Cell Lung and Gastric Cancers
7/7/2021
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced a clinical supply agreement with Regeneron for Libtayo® (cemiplimab).
-
Silverback Therapeutics to Participate in the Raymond James Human Health Innovation Conference
6/15/2021
Silverback Therapeutics, Inc. today announced that the Company will participate in the Raymond James Human Health Innovation Conference.
-
Silverback Therapeutics to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
6/1/2021
Silverback Therapeutics to Participate in the Goldman Sachs 42 nd Annual Global Healthcare Conference
-
Silverback Therapeutics Reports First Quarter 2021 Financial Results
5/13/2021
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a business update.
-
Silverback Therapeutics to Present SBT6290 Preclinical Data at the AACR 2021 Annual Conference
4/8/2021
Silverback Therapeutics, Inc. will present preclinical data on its second product candidate, SBT6290, at the American Association of Cancer Research (AACR) 2021 Annual Conference, taking place virtually April 10-15.
-
Silverback Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Updates
3/29/2021
Initiated SBT6050 clinical development, with pharmacological activity demonstrated in the first dose cohort Advanced preclinical development of SBT6290 and declared SBT8230 as the development candidate for chronic hepatitis B virus program Raised $441.2 million including $277.7 million in gross proceeds from our IPO $386.6 million in cash and cash equivalents at end of 2020
-
Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors
3/15/2021
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the appointment of Maria Koehler, M.D., Ph.D. to Silverback’s Board of Directors.
-
Silverback Therapeutics to Present at Upcoming Investor Conferences
2/16/2021
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Laura Shawver, Ph.D., Silverback’s chief executive officer, will present at the following upcoming investors conferences
-
December is bringing frost in the North and plenty of cold, hard cash for these life sciences companies.
-
Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
12/8/2020
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the closing of its previously announced initial public offering of 13,225,000 shares of its common stock,
-
Silverback Therapeutics Announces Pricing of Initial Public Offering - Dec 04, 2020
12/4/2020
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, announced the pricing of its initial public offering of 11,500,000 shares of its common stock at a price to the public of $21.00 per share.
-
Upping the numbers two times, Silverback now readies a 10 million share offering.
-
Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting Digital Experience
11/13/2020
Silverback Therapeutics, Inc. (“Silverback”) (“the Company”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue-targeted therapeutics, will present preclinical data for SBT8230 at AASLD The Liver Meeting Digital Experience (November 13-16, 2020).
-
BioSpace Movers & Shakers, November 13
11/13/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Silverback Therapeutics Expands Executive Team With Appointment of Healthcare Investment Banking Veteran Jonathan Piazza as Chief Financial Officer
11/10/2020
Silverback Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer and other serious diseases, today announced the appointment of Jonathan Piaz
-
Silverback Therapeutics to Present Data on Two Programs at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting
11/9/2020
Silverback Therapeutics to Present Data on Two Programs at The Society for Immunotherapy of Cancer’s (SITC) 35 th Anniversary Annual Meeting ⎯ Trial-in-progress update on the Phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to TLR8 agonist, in subjects with advanced HER2-expressing solid tumors ⎯ Preclinical data on SBT6290, a Nectin4-directed monoclonal antibody conjugated to a TLR8 agonist SEATTLE--( BUSINESS WIRE )-
-
Silverback Therapeutics Raises $85 Million in Series C Financing; Company Announces Executive Promotions
9/23/2020
Silverback Therapeutics, Inc. (“Silverback”) (“the Company”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform
-
Clinical Catch-Up: August 24-28
8/31/2020
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.